MiR-193b-3p-ERBB4 axis regulates psoriasis pathogenesis via modulating cellular proliferation and inflammatory-mediator production of keratinocytes

Cell Death Dis. 2021 Oct 19;12(11):963. doi: 10.1038/s41419-021-04230-5.

Abstract

Psoriasis is an auto-inflammatory skin disease characterized by abnormal activation of epidermal keratinocytes, aberrant neovascularization, and dysregulation of immune cells. MicroRNAs are small non-coding RNAs that mainly function in the post-transcriptional regulation of gene expression. Recently, accumulating evidence has demonstrated that expression of microRNAs is dysregulated in psoriasis patients and microRNAs play key roles in psoriasis pathogenesis. Downregulation of miR-193b-3p has been identified to be associated with psoriasis development. However, the precise functions and action mechanisms of miR-193b-3p in psoriasis pathogenesis remain unclear. In this study, we confirmed the downregulation of miR-193b-3p in psoriasis patients, psoriasis-like inflammatory cellular models, and an imiquimod (IMQ) -induced mouse model. A negative correlation was found between miR-193b-3p level and patient Psoriasis Area and Severity Index (PASI) score. Furthermore, miR-193b-3p suppressed proliferation, inflammatory-factor secretion, and the STAT3 and NF-κB signaling pathways in keratinocytes. Importantly, intradermal injection of agomiR-193b-3p blocked, whereas antagomiR-193b-3p augmented, the psoriasis-like inflammation in the IMQ-induced mouse model. Bioinformatics analysis and the dual-luciferase reporter assay showed that miR-193b-3p targets ERBB4 3' untranslated region (UTR). In addition, ERBB4 induced proliferation, inflammatory-factor production, and the STAT3 and NF-κB pathways in keratinocytes. Most importantly, forced expression of ERBB4 could attenuate the effects of miR-193b-3p in keratinocytes, indicating that miR-193b-3p inhibits keratinocyte activation by directly targeting ERBB4. In conclusion, our findings demonstrated that the miR-193b-3p-ERBB4 axis underlies the hyperproliferation and aberrant inflammatory-factor secretion of psoriatic keratinocytes, providing a novel, microRNA-related causal mechanism and a potential therapeutic target in psoriasis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antagomirs / pharmacology
  • Base Sequence
  • Cell Proliferation / genetics
  • Disease Models, Animal
  • Down-Regulation / genetics
  • Female
  • HaCaT Cells
  • Humans
  • Imiquimod / adverse effects
  • Inflammation / genetics
  • Inflammation / pathology
  • Inflammation Mediators / metabolism*
  • Keratinocytes / metabolism*
  • Keratinocytes / pathology*
  • Male
  • Mice
  • Mice, Inbred C57BL
  • MicroRNAs / genetics
  • MicroRNAs / metabolism*
  • Models, Biological
  • Psoriasis / chemically induced
  • Psoriasis / genetics*
  • Psoriasis / pathology*
  • RNA, Messenger / genetics
  • RNA, Messenger / metabolism
  • Receptor, ErbB-4 / metabolism*
  • Skin / pathology

Substances

  • Antagomirs
  • Inflammation Mediators
  • MIRN193 microRNA, human
  • MicroRNAs
  • RNA, Messenger
  • ERBB4 protein, human
  • Receptor, ErbB-4
  • Imiquimod